From May 2016 till May 2018 all breast cancer patients with operable disease submitted to surgery after neoadjuvant treatment would be divided in four groups considering initially clinical axillary stage, axillary procedure that was done, axillary response to preoperative systemic treatment and pathological axillary stage. In first postoperative year all patients will be monitored for appearance of locoregional and distant recurrence.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Regional recurrence
Timeframe: 3 years
Distant recurrence (progression)
Timeframe: 3 years